 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new data on...

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the U.S. Food and Drug...

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma (NASDAQ:URGN - Get Free Report)s stock had its "buy" rating reissued by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a...

HC Wainwright Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

UroGen Pharma files patent infringement action against Teva Pharmaceuticals

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has filed a...

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

Investors eyeing a purchase of UroGen Pharma Ltd (URGN) stock, but tentative about paying the going market price of 13.88/share, might benefit from considering selling puts among the alternative...

Commit To Purchase UroGen Pharma At $10, Earn 20.3% Annualized Using Options

This indicator may be signaling that URGN's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

UroGen Pharma (URGN, $14.18) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling URGN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

UroGen Pharma (URGN, $15) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

For the last three days, A.I.dvisor has detected that URGN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

UroGen Pharma (URGN, $14.94) Aroon Indicator entered a Downtrend on March 27, 2024.

UroGen Pharma (URGN, $15.21) Aroon Indicator entered a Downtrend on March 26, 2024.

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Volume (M)	315,348.00
52-Wk High	$24.13
52-Wk Low	$8.69

URGN UroGen Pharma Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals